NTRBW

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
Ken GriffinCitadel Advisors $-192.2K ExitQ1 2026 $192k -- $1.00
Ken GriffinCitadel Advisors $-5.4K TrimQ3 2025 $5.4k -- $1.00
Ken GriffinCitadel Advisors $1.3K AddQ2 2025 $1.3k -- $1.00
Ken GriffinCitadel Advisors $44.1K AddQ1 2025 $44k -- $1.00
Ken GriffinCitadel Advisors $35.7K AddQ4 2024 $36k -- $1.00
Ken GriffinCitadel Advisors $69.6K AddQ3 2024 $70k -- $1.00

News

globenewswire.comNutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM Conferenceglobenewswire.comMay 15

globenewswire.comNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel Podcastglobenewswire.comApr 22

globenewswire.comNutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl Patchglobenewswire.comMar 30

Trade NTRBW

About Nutriband Inc.

Nutriband Inc. is a pharmaceutical company dedicated to advancing a diverse pipeline of transdermal drug products. Foremost among its developmental initiatives is an abuse-deterrent fentanyl transdermal system. This innovative patch aims to provide both healthcare providers and patients with an extended-release fentanyl solution for the effective management of chronic pain. Beyond its core transdermal portfolio, Nutriband Inc. also holds a licensing agreement with Rambam Med-Tech Ltd. for the development of RAMBAM Closed System Transfer Devices. Established in 2016, the company maintains its corporate headquarters in Orlando, Florida.

CEO: Gareth Sheridan
IPO Date: Oct 1, 2021

Market Data

Market data refresh is queued when this stock page is viewed.

Valuation

Valuation snapshot is not available yet.

Financials

Financial statement snapshot is not available yet.

Events

EarningsJul 1